DJI Osmo Action 4 Camera with Dual Touchscreens Sees Price Crash, Did Amazon Make a Mistake?
You can get the DJI Osmo Action 4 standard combo for $209 today, discounted from its regular $299. That's a nice 30% discount, the lowest Amazon has offered this camera. Even better, this is a sale open to everyone (Prime member or not) so it's one you'll not want to miss.
See at Amazon
At its heart lies a spacious 1/1.3-inch sensor, implying finer image quality particularly in difficult lighting conditions. Whether shooting at sunrise or sunset, or in low-light environments, this camera captures clear footage with great clarity. 4K video at up to 120 frames per second enables you to capture fantastically smooth slow-motion footage, perfect for sport, travel, or creative use when detail matters.
One of the Osmo Action 4's strengths in comparison to its competitors is its ability to function in low light: With the help of advanced sensor technology and DJI image processing, you experience vivid real-life colors and sharp captures even after dark. The camera also incorporates 10-bit color and D-Log M color profiles which provide creators with more room to maneuver when editing and your videos will look filmic and professional.
It's made to go wherever your trip takes you with a water-resistant case that lets you dive as deep as 18 meters without ever needing a special casing. Surf, snorkel, get swept up in an unexpected rainstorm and your camera's got you covered. The hearty build construction means you can count on it to withstand bumps, drops, and whatever else you dish out in the great great outdoors.
Battery life is always a concern with action cameras but the Osmo Action 4 addresses this with a long-lasting battery that can keep recording for up to 160 minutes on a single charge. That's more than enough for a full day of exploring and the fast-charging capability means you'll spend less time waiting and more time capturing memories. The dual touchscreen design (one on the front and one on the back) makes framing shots, reviewing footage and adjusting settings quick and intuitive.
For Prime Day, the DJI Osmo Action 4 at $209 is a deal you can't pass up.
See at Amazon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
a minute ago
- Wall Street Journal
Exclusive: White House to Target 'Debanking'
The White House plans to step up pressure against banks over perceived discrimination against conservatives and crypto companies, with an executive order that threatens to fine lenders that drop customers for political reasons. A draft of the order, which was viewed by The Wall Street Journal, directs regulators to investigate whether any financial institutions might have violated the Equal Credit Opportunity Act, antitrust laws or consumer financial protection laws. 🔎 Go deeper:
Yahoo
29 minutes ago
- Yahoo
Editorial: More unlawful tariffs: Trump has no authority to institute damaging trade barriers
On Friday, Donald Trump followed up a concerning jobs report with massive new global tariffs, driving markets down and once more raising prices on consumers for no reason after weeks of supposed trade negotiations. Like with his first round of import duties, announced in the Rose Garden on his ludicrous April 2 'Liberation Day,' these tariffs are not only chaotic and destructive, but they're illegal. The president is leaning on a 1977 law meant to be invoked for targeted financial actions in certain emergency circumstances to reshape trade globally. Just the day before these newest tariffs were implemented, the administration's lawyers had been grilled by the 11 judges of the U.S. Court of Appeals for the Federal Circuit in Washington, who pointed out among other things that the law doesn't even mention tariffs at all. If the plaintiffs, made up of states and businesses, need anywhere to look for inspiration and evidence for their legal arguments, they don't have to look much further than Trump's own ramblings and social media feed, where he constantly tells the whole world that he is engaging in the tariff actions for all manner of reasons completely unrelated to any economic objectives. So far, he's threatened tariffs over Brazil's domestic prosecution of its former president Jair Bolsonaro and over Canada's intent to recognize a Palestinian state, among other things. This is a real disparate set of rationales, but what they have in common is that they are ideological battles probably drawn from something Trump saw on TV and have nothing to do with correcting a supposed trade imbalance with those countries, already an incredibly flimsy argument to begin with. Don't just take our word for it; the Manhattan-based U.S. Court of International Trade — you know, the judicial entity set up specifically and explicitly to have expertise on these matters — already struck down most of Trump's tariff regime on the grounds that it was unlawful. That ruling has been stayed for now, but the evidence just keeps piling on that Trump is significantly exceeding his authority. Unfortunately, even if this insanity were to be fully struck down tomorrow, we've had months of chaos that has indelibly damaged trade relationships as well as general diplomatic relations. The world is not going to wait for the U.S. to hash out its chaos, and other countries are already moving to reorient parts of their manufacturing and trade schemes to circumvent an unreliable United States. Of course, this seems like one more issue headed at some point to the U.S. Supreme Court, perhaps the shadow docket where the court these days like to conduct its unsigned pro-Trump business. It's long since become clear that the high court is more interested in ideological outcomes than the uniform application of the law, but even then, siding with Trump here would be farcical. This is the exact same court that just last year ruled that Joe Biden attempting to clear some student debt by invoking emergency powers in the context of the COVID pandemic — a real global catastrophe that killed countless people and crashed the economy while putting millions out of work — was an unlawful exercise of authority. If that's the case, but Trump is in his rights to wildly alter tariff policies at a whim in service to random political grievances around the world, then the law truly means nothing anymore. Let's stop this madness while we still can, before economic forces take it out of our hands. ___
Yahoo
29 minutes ago
- Yahoo
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
